{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T18:27:13Z","timestamp":1791311233886,"version":"4.3.1"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2003,6,1]],"date-time":"2003-06-01T00:00:00Z","timestamp":1054425600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2003,6,1]],"date-time":"2003-06-01T00:00:00Z","timestamp":1054425600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2003,6]]},"DOI":"10.1023\/a:1024038127156","type":"journal-article","created":{"date-parts":[[2003,9,12]],"date-time":"2003-09-12T21:07:28Z","timestamp":1063400848000},"page":"391-397","source":"Crossref","is-referenced-by-count":199,"title":["Use of the Peroxisome Proliferator-Activated Receptor (PPAR) \u03b3 Ligand Troglitazone as Treatment for Refractory Breast Cancer: A Phase II Study"],"prefix":"10.1007","volume":"79","author":[{"given":"Harold J.","family":"Burstein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George D.","family":"Demetri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Mueller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pasha","family":"Sarraf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce M.","family":"Spiegelman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric P.","family":"Winer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"5124397_CR1","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/35013000","volume":"405","author":"S Kersten","year":"2000","unstructured":"Kersten S, Desvergne B, Wahli W: Roles of PPARs in health and disease. Nature 405: 421-425, 2000","journal-title":"Nature"},{"key":"5124397_CR2","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1146\/annurev.med.53.082901.104018","volume":"53","author":"J Berger","year":"2002","unstructured":"Berger J, Moller DE: The mechanisms of action of PPARs. Annu Rev Med 53: 409-435, 2002","journal-title":"Annu Rev Med"},{"key":"5124397_CR3","doi-asserted-by":"crossref","first-page":"61","DOI":"10.7326\/0003-4819-134-1-200101020-00014","volume":"134","author":"AA Parulkar","year":"2001","unstructured":"Parulkar AA, Pendergraass ML, Granda-Ayala R, Lee TR, Fonseca VA: Nonhypoglycemic effects of thiazolidinedionies. Ann Int Med 134: 61-71, 2001","journal-title":"Ann Int Med"},{"key":"5124397_CR4","doi-asserted-by":"crossref","first-page":"507","DOI":"10.2337\/diabetes.47.4.507","volume":"47","author":"BM Spiegelman","year":"1998","unstructured":"Spiegelman BM: PPAR-\u03b3: adipogenic regulator and thiazolidinedione receptor. Diabetes 47: 507-514, 1998","journal-title":"Diabetes"},{"key":"5124397_CR5","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1021\/jm950395a","volume":"39","author":"TM Willson","year":"1996","unstructured":"Willson TM, Cobb JE, Cowan DJ et al.: The structure-activity relationship between peroxisome proliferator-activated receptor gamma agonism and the antihyperglycemic activity of thiazolidinediones. J Med Chem 39: 665-668, 1996","journal-title":"J Med Chem"},{"key":"5124397_CR6","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/S0092-8674(00)81359-8","volume":"87","author":"BM Spiegelman","year":"1996","unstructured":"Spiegelman BM, Flier JS: Adipogenesis and obesity: rounding out the big picture. Cell 87: 377-389, 1996","journal-title":"Cell"},{"key":"5124397_CR7","doi-asserted-by":"crossref","first-page":"3951","DOI":"10.1073\/pnas.96.7.3951","volume":"96","author":"GD Demetri","year":"1999","unstructured":"Demetri GD, Fletcher CDM, Mueller E et al.: Induction of solid tumor differentiation by the peroxisome proliferatoractivated receptor-\u03b3 ligand troglitazone in patients with liposarcoma. Proc Natl Acad Sci 96: 3951-3956, 1999","journal-title":"Proc Natl Acad Sci"},{"key":"5124397_CR8","first-page":"535a","volume":"18","author":"GD Demetri","year":"1999","unstructured":"Demetri GD, Spiegelman B, Fletcher CD et al.: Differentiation of liposarcomas in patients treated with PPAR \u03b3 ligand troglitazone: documentation of biological activity in myxoid\/ round cell and pleomorphic subtypes. Proc AmSoc Clin Oncol 18: 535a, 1999 (abstract 2064)","journal-title":"Proc AmSoc Clin Oncol"},{"key":"5124397_CR9","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1038\/1990","volume":"4","author":"B Seed","year":"1998","unstructured":"Seed B: PPAR\u03b3 and colorectal carcinoma: conflicts in a nuclear family. Nat Med 4: 1004-1005, 1998","journal-title":"Nat Med"},{"key":"5124397_CR10","first-page":"3344","volume":"58","author":"T Kubota","year":"1998","unstructured":"Kubota T, Koshizuka K, Williamson EA et al.: Ligand for peroxisome proliferator-activated receptor gamma (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo. Cancer Res 58: 3344-3352, 1998","journal-title":"Cancer Res"},{"key":"5124397_CR11","doi-asserted-by":"crossref","first-page":"10990","DOI":"10.1073\/pnas.180329197","volume":"97","author":"E Mueller","year":"2000","unstructured":"Mueller E, Smith M, Sarraf P et al.: Effects of ligand activation of peroxisome proliferator-activated receptor gamma in human prostate cancer. Proc Natl Acad Sci 97: 10990-10995, 2000","journal-title":"Proc Natl Acad Sci"},{"key":"5124397_CR12","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/S1097-2765(00)80047-7","volume":"1","author":"E Mueller","year":"1998","unstructured":"Mueller E, Sarraf P, Tontonoz P et al.: Terminal differentiation of human breast cancer through PPAR?. Mol Cell 1: 465-470, 1998","journal-title":"Mol Cell"},{"key":"5124397_CR13","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1006\/bbrc.2001.5491","volume":"286","author":"F Yin","year":"2001","unstructured":"Yin F, Wakino S, Liu Z et al.: Troglitazone inhibits growth of MCF-7 breast carcinoma cells by targeting G1 cell cycle regulators. Biochem Biophys Res Commun 286: 916-922, 2001","journal-title":"Biochem Biophys Res Commun"},{"key":"5124397_CR14","doi-asserted-by":"crossref","first-page":"8806","DOI":"10.1073\/pnas.95.15.8806","volume":"95","author":"E Elstner","year":"1998","unstructured":"Elstner E, Muller C, Koshizuka K et al.: Ligands for peroxisome proliferator-activated receptor \u03b3 and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. Proc Natl Acad Sci 95: 8806-8811, 1998","journal-title":"Proc Natl Acad Sci"},{"key":"5124397_CR15","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1093\/jnci\/92.5.418","volume":"92","author":"RG Mehta","year":"2000","unstructured":"Mehta RG, Williamson E, Patel MK, Koeffler HP: A ligand of peroxisome proliferator-activated receptor g, retinoids, and prevention of preneoplastic mammary lesions. J Natl Cancer Inst 92: 418-423, 2000","journal-title":"J Natl Cancer Inst"},{"key":"5124397_CR16","first-page":"5671","volume":"59","author":"N Suh","year":"1999","unstructured":"Suh N, Wang Y, Williams CR et al.: A new ligand for the peroxisome proliferator-activated receptor-\u03b3 (PPAR-\u03b3), PPAR\u03b3 ligand troglitazone for refractory breast cancer 397 GW7845, inhibits rat mammary carcinogenesis. Cancer Res 59: 5671-5673, 1999","journal-title":"Cancer Res"},{"key":"5124397_CR17","doi-asserted-by":"crossref","first-page":"89","DOI":"10.2165\/00003495-199754010-00010","volume":"54","author":"CM Spencer","year":"1997","unstructured":"Spencer CM, Markham A: Troglitazone. Drugs 54: 89-101, 1997","journal-title":"Drugs"},{"key":"5124397_CR18","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1016\/S0140-6736(00)04960-6","volume":"357","author":"EAM Gale","year":"2001","unstructured":"Gale EAM: Lessons from the glitazones: a story of drug development. Lancet 357: 1870-1875, 2001","journal-title":"Lancet"},{"key":"5124397_CR19","first-page":"51a","volume":"21","author":"FJ Esteva","year":"2002","unstructured":"Esteva FJ, Glaspy JA, Baidas SM et al.: Multicenter phase II study of oral bexarotene for patients with metastatic breast Cancer. Proc Am Soc Clin Oncol 21: 51a, 2002 (abstract 203)","journal-title":"Proc Am Soc Clin Oncol"},{"key":"5124397_CR20","doi-asserted-by":"crossref","first-page":"4117","DOI":"10.1242\/jcs.114.22.4117","volume":"114","author":"M Pignatelli","year":"2001","unstructured":"Pignatelli M, Cortes-Canteli M, Lai C, Santos A, Perez-Castillo A: Peroxisome proliferator-activated receptor \u03b3 is an inhibitor of erbBs activity in human breast cancer cells. J Cell Sci 114: 4117-4126, 2001","journal-title":"J Cell Sci"},{"key":"5124397_CR21","first-page":"1604","volume":"60","author":"GL Rubin","year":"2000","unstructured":"Rubin GL, Zhao Y, Kalus AM, Simpson ER: Peroxisome proliferator-activated receptor g ligands inhibit estrogen biosynthesis in human breast adipose tissue: possible implications for breast cancer therapy. Cancer Res 60: 1604-1608, 2000","journal-title":"Cancer Res"},{"key":"5124397_CR22","doi-asserted-by":"crossref","first-page":"13771","DOI":"10.1073\/pnas.162480299","volume":"99","author":"GD Girnun","year":"2002","unstructured":"Girnun GD, Smith WM, Drori S et al.: APC-dependent suppression of colon carcinogenesis by PPAR?. Proc Natl Acad Sci USA 99: 13771-13776, 2002","journal-title":"Proc Natl Acad Sci USA"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1023\/A:1024038127156.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1023\/A:1024038127156\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.springerlink.com\/index\/pdf\/10.1023\/A:1024038127156","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1023\/A:1024038127156.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T23:45:05Z","timestamp":1750895105000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1023\/A:1024038127156"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,6]]},"references-count":22,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2003,6]]}},"alternative-id":["5124397"],"URL":"https:\/\/doi.org\/10.1023\/a:1024038127156","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,6]]}}}